PTC Therapeutics (PTCT) Misses Q1 EPS by 24c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
May 3, 2022 4:01 PM EDT- $149 million total revenue representing impressive 26% year-over-year growth
- Initiation of PIVOT-HD Phase 2 trial of PTC518 in Huntington's disease
- CHMP opinion on AADC gene therapy expected in May; ready to execute on potential launch
SOUTH PLAINFIELD, N.J., May 3, 2022 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2022.
"We are continuing to build a robust... More
